四川安可康生物医药公司溶瘤病毒获得FDA批准进入临床试验_老虎社区_美港股上老虎

四川安可康生物医药公司溶瘤病毒获得FDA批准进入临床试验

财见
2024-02-04

四川安可康生物医药有限公司开发的双矛I型溶瘤病毒(DS1-H2-1)获美国食品和药品监督管理局(FDA)批准，进入神经母细胞瘤的临床I/II期试验。公司计划将该病毒应用范围扩展到其他类型的神经类肿瘤和实体瘤治疗。(医药健闻)

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":270375255154976,"tweetId":"270375255154976","gmtCreate":1707017440526,"gmtModify":1707017442438,"author":{"id":4100392628064900,"idStr":"4100392628064900","authorId":4100392628064900,"authorIdStr":"4100392628064900","name":"财见","avatar":"https://static.tigerbbs.com/8c74fd467f3aa41e2407f74bf83f57ee","vip":5,"userType":5,"introduction":"美通社1954年开创了企业新闻稿发布行业的先河，于2016年成为Cision 旗下公司。","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":3975,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"四川安可康生物医药公司溶瘤病毒获得FDA批准进入临床试验","html":"<html><head></head><body>\n四川安可康生物医药有限公司开发的双矛I型溶瘤病毒(DS1-H2-1)获美国食品和药品监督管理局(FDA)批准，进入神经母细胞瘤的临床I/II期试验。公司计划将该病毒应用范围扩展到其他类型的神经类肿瘤和实体瘤治疗。(医药健闻)</body></html>","htmlText":"<html><head></head><body>\n四川安可康生物医药有限公司开发的双矛I型溶瘤病毒(DS1-H2-1)获美国食品和药品监督管理局(FDA)批准，进入神经母细胞瘤的临床I/II期试验。公司计划将该病毒应用范围扩展到其他类型的神经类肿瘤和实体瘤治疗。(医药健闻)</body></html>","text":"四川安可康生物医药有限公司开发的双矛I型溶瘤病毒(DS1-H2-1)获美国食品和药品监督管理局(FDA)批准，进入神经母细胞瘤的临床I/II期试验。公司计划将该病毒应用范围扩展到其他类型的神经类肿瘤和实体瘤治疗。(医药健闻)","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/270375255154976","repostId":0,"isVote":1,"tweetType":1,"viewCount":35209,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["399441","161726","03347","300347"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":199,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}